Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT02474160Recruiting
Banking cancer tissue and blood for future research
This study collects and stores leftover or newly taken samples of tissue and blood from people with cancer. The goal is to build a research library that can help investigators study cancer and develop better tests or treatments.
New York, New YorkAges 2 months+ - NCT02468024RecruitingPhase 3
Surgery or focused radiation for early lung cancer
This study compares two treatments—removing only part of the lung (sublobar resection) versus a focused radiation approach (stereotactic ablative radiotherapy)—for early-stage non-small cell lung cancer. It aims to see which option works better with fewer problems for the right patients.
Syracuse, New YorkAges 18 years+ - NCT02620852Recruiting
Wisdom Study: Women’s breast cancer screening decisions
This study looks at how to decide the best breast cancer screening (like mammograms) based on your personal risk. It may help by testing a smarter way to match screening to your risk level.
New York, New YorkAges 30–74 - NCT00870129Recruiting
MRI mapping to plan radiation for certain brain tumors
This study uses MRI scans to find higher-risk areas in certain brain and other solid tumors and help plan radiation treatment. It also looks for changes in tumor “metabolites” (chemicals in the tumor) that may relate to how the tumor behaves.
New York, New YorkAges 18 years+ - NCT00301119Recruiting
Lung cancer screening using risk factors and test results
This study looks at how to find lung cancer earlier by screening people based on their lung-cancer risk. It may help doctors decide who needs further testing if lung nodules are found.
New York, New YorkAges 50 years+ - NCT00843375Recruiting
Testing stool samples to find early colon cancer and polyps
This study checks stool samples to see how well stool tests can detect early colon cancer and precancerous growths called adenomas. If you qualify, you’ll collect stool samples for a lab test (FIT) and sometimes this helps sort who should get follow-up testing.
New York, New YorkAges 18 years+ - NCT01102569Recruiting
Genetic research for pancreatic cancer in Ashkenazi Jewish patients
This study looks at genetic (DNA) factors related to pancreatic cancer. It may help researchers understand risks and find ways to improve prevention or treatment for people in the study population.
New York, New YorkAges 18–85 - NCT01120353Recruiting
Childhood cancer survivors study to understand long-term health
This study follows people who survived certain childhood cancers to learn what long-term health effects may happen after treatment. It also compares survivors with siblings to help researchers understand differences that may be related to cancer or treatment.
New York, New YorkAges Any age - NCT01109394Recruiting
Help study tumors with sample testing and a research biology library
This study collects tumor (or related) samples to analyze their genes and build a shared research “biobank.” It may help researchers understand cancers better for future diagnosis and treatments.
New York, New YorkAges 4 weeks+ - NCT07619079Recruiting
Registry for people with early colorectal cancer in a polyp
This study collects information from people who have had a malignant polyp removed from the colon. It helps doctors learn more about this early stage of colorectal cancer and may help guide future care.
Commack, New YorkAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Buffalo, New YorkAges 60 years+ - NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Rochester, New YorkAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Buffalo, New YorkAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Buffalo, New YorkAges 18 years+ - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Buffalo, New YorkAges 18 years+ - NCT07874490RecruitingPhase 2
Osimertinib plus cyclosporine for advanced lung cancer
This study tests whether adding cyclosporine to the standard drug osimertinib can make it work better in people with advanced non-small cell lung cancer that has a specific EGFR gene change. You can join even if you haven't started treatment or have just started osimertinib within the last 3 weeks.
New York, New YorkAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
New York, New YorkAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Shirley, New YorkAges 18 years+ - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
New York, New YorkAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Buffalo, New YorkAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Cooperstown, New YorkAges 18–100 - NCT05947695Recruiting
Nurse-led comfort and survivorship care for advanced cancer
This study looks at whether a specialized nurse-led care plan soon after diagnosis/treatment helps people living with advanced (metastatic) cancer. It focuses on patients expected to do better than average based on certain prognosis factors.
West Islip, New YorkAges 21 years+ - NCT07856732RecruitingPhase 1
Silver dressing for head and neck cancer patients with tracheostomy
This study tests a special silver dressing called Silverlon for people with head and neck cancer who have a tracheostomy. The dressing may help prevent infections and improve healing around the tracheostomy site.
Syracuse, New YorkAges 18 years+ - NCT07832292RecruitingPhase 2
Study of an investigational drug for metastatic prostate cancer
This trial tests an experimental drug (JNJ-101556143) for men with metastatic prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can slow down or stop the cancer from growing.
Syracuse, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Roswell Park Comprehensive Cancer Center · 6 studies
- Memorial Sloan Kettering Cancer Center · 5 studies
- Montefiore Medical Center · 4 studies
- Columbia University Irving Medical Center · 3 studies
- NYU Langone Health · 3 studies
- University of Rochester · 3 studies
- Weill Cornell Medicine · 3 studies
- Associated Medical Professionals of NY · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.